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BACKGROUND: The Coxsackie and adenovirus receptor (CAR) has been shown to inhibit cancer cell proliferation, migration, and
invasion. The underlying mechanisms, however, are poorly understood.
METHODS: The differential gene expression in the human colon cancer cell line DLD1 on RNAi-mediated functional CAR knockdown
was analysed using oligo-array technology. Expression of a-catenin was determined by quantitative RT-PCR and western blotting.
Proliferation, migration, and invasion after CAR knockdown were assessed by in vitro assays, and cell morphology in a three-
dimensional context was evaluated using matrigel.
RESULTS: Oligo-array technology identified a-catenin as the strongest downregulated gene after CAR knockdown. Western blotting
and quantitative RT-PCR confirmed a reduced a-catenin expression after CAR knockdown in DLD1 cells and in the rat intestinal cell
line IEC-6. Functionally, both cell lines showed a marked increase in proliferation, migration, and invasion on CAR knockdown. In
matrigel, both cell lines formed amorphous cell clusters in contrast to well-organised three-dimensional structures of CAR-expressing
vector controls. Ectopic ‘re’-expression of a-catenin in DLD1 and IEC-6 CAR knockdown cells reversed these functional and
morphological effects.
CONCLUSION: These data suggest that an interaction of CAR and a-catenin mediates the impact of CAR on cell proliferation,
migration, invasion, and morphology.
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The Coxsackie and adenovirus receptor (CAR) was first charac-
terised as a viral attachment site on the surface of epithelial cells
and was later identified as an integral component of the tight
junction complex (Coyne and Bergelson, 2005). In several human
carcinomas, particularly in more advanced stages, a reduced
CAR presence was found, partially associated with loss of tumour
differentiation, increased infiltration, and poor prognosis
(Sachs et al, 2002; Matsumoto et al, 2005; Korn et al, 2006;
Buscarini et al, 2007; Okegawa et al, 2007; Anders et al, 2009). On
the basis of data from studies in cell lines, it has been speculated
that loss of CAR promotes the proliferation, migration, and
invasion of cancer cells (Okegawa et al, 2000, 2001; Bruning and
Runnebaum, 2003, 2004; Huang et al, 2005; Wang et al, 2005).
These phenomena are believed to result from an impaired
intercellular adhesion (Okegawa et al, 2000; Bruning and
Runnebaum, 2004; Wang et al, 2005). Recently, it has been shown
that CAR interacts with microtubules, and therefore contributes
to the cytoskeletal equilibrium and inhibits cell migration (Fok
et al, 2007). A more detailed insight into the mechanisms
underlying the influence of CAR on cancer cell pathobiology,
however, is lacking.
Aiming to further elucidate genes that facilitate the proposed
function of CAR in cancer, we determined differential gene
expression after CAR knockdown in the human colon cancer cell
line DLD1 and assessed the functional impact of the strongest
regulated gene a-catenin.
MATERIALS AND METHODS
Cell culture and generation of transfected cell lines
The human colon cancer cell line DLD1 and the rat small intestine
cell line IEC-6 were obtained from the American Type Culture
Collection (Rockville, MD, USA) and from the Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH (Braunschweig,
Germany), respectively, and were cultured in recommended growth
media. Three-dimensional cultures were set up as described
previously (Anders et al, 2003b). In brief, cell lines were cultured
to confluence as monolayers and subsequently embedded into a
commercially prepared reconstituted basement membrane from
Engelbreth–Holm–Swarm tumours (BD Biosciences, Bedford,
MA, USA). Cell lines with a functional CAR knockdown using
CAR-specific siRNAs were generated as described previously
(Anders et al, 2009). In this study, either a CAR-specific siRNA,
CCAAGUACCAAGUGAAGACdTdT, or a control siRNA, CAC
AAAAGUAUCGCGCAAGdTdT, cloned into the ‘pSuper’ vector
system (Oligoengine, Seattle, WA, USA) was transfected into cell
lines using Effectene (Quiagen, Hilden, Germany). The ectopic
expression of a-catenin was accomplished by the stable transfection
of a human full-length a-catenin cDNA (a kind gift from M Ozawa,
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sKagoshima University, Kagoshima, Japan) as described previously
(Matsubara and Ozawa, 2004). The differential expression of CAR
and the a-catenin protein in pooled cell populations was determined
by western blotting.
Oligo-array analysis
Total RNA was isolated using Trizol (Invitrogen, Karlsruhe, Germany)
and reverse transcribed with oligo-dT primers and SuperScript II
(Invitrogen). cDNAs generated from 200ng of total RNA were
analysed for differential gene expression using HG U133 2.0 plus chips
(Affymetrix, Santa Clara, CA, USA) and processed using GeneSpring
software (Agilent Technologies, Inc., Palo Alto, CA, USA).
Western blotting
Protein lysates were obtained as previously described (Anders
et al, 2003a). Equal amounts of protein lysates were loaded onto
reducing Laemmli gels, immunoblotted with specific antibodies
against CAR (H-300: sc-15405; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), a-catenin, ZO-1 (both Zymed Laboratories, South
San Francisco, CA, USA), or b-Actin (Sigma-Aldrich, Munich,
Germany), and detected using the enhanced chemiluminescence
system (Amersham Pharmacia, Piscataway, NJ, USA).
Quantitative mRNA determination
Total RNA was isolated using Trizol (Invitrogen) and was reverse
transcribed with oligo-dT primers and SuperScript II (Invitrogen).
cDNAs generated from 200ng of total RNA were used for real-time
RT-PCR assays on a Stratagene MX3000P cycler using a-catenin
gene-specific primers (CCATGCAGGCAACATAAACTTC and
AGGGTTGTAACCTGTGTAACAAG) and the qPCR MasterMix
for SYBR Green I (Eurogentec Deutschland GmbH, Ko ¨ln,
Germany). Quantification was carried out by the comparative
DCT method normalising CT values to b-actin (DLD1) or 18S
(IEC-6). cDNAs derived from CHO and CHO-CAR cells were used
as negative and positive controls, respectively. All experiments
were carried out in triplicate and repeated at least twice.
Immunofluorescence
Immunofluorescence staining was carried out as described
previously (Anders et al, 2003a). In brief, anti-CAR (H-300:
sc-15405; Santa Cruz Biotechnology) and anti-a-catenin (Zymed
Laboratories) antibodies served as primary antibodies; a Cy2-
conjugated anti-rabbit antibody and a Cy3-conjugated anti-mouse
antibody were used as secondary antibodies (Dianova GmbH,
Hamburg, Germany). Multicolour fluorescence microscopy was
carried out using a Zeiss Axiophot microscope (Carl Zeiss AG,
Jena, Germany).
Co-immunoprecipitation
Co-immunoprecipitations were carried out using the Immuno-
precipitation Kit Protein G (Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer’s instructions. In brief,
anti-CAR (H-300: sc-15405; Santa Cruz Biotechnology) and anti-
a-catenin (Zymed Laboratories) antibodies served as antibodies
for the initial immunoprecipitation; IgG rabbit (Dianova GmbH)
was used as control. Subsequent western blotting was carried out
as described above.
Assessment of cell proliferation
Cells were seeded onto six-well plates (4 10
5 cells per well for
DLD1 and 2 10
5 cells per well for IEC-6) in recommended media.
After 48h, the cells were detached using trypsin, stained with trypan
blue to exclude dead cells, and counted using a haematocytometer
counting chamber (VWR International, Darmstadt, Germany). All
experiments were carried out in triplicate and repeated at least twice.
Determination of cell migration
Assessment of directed cancer cell migration was carried out using
an AP48 48 Well Micro Chemotaxis Chamber (Neuro Probe,
Gaithersburg, MD, USA). Here, 50000 cells per well in 50ml fetal
calf serum (FCS)-free media were seeded onto the upper part of
the chamber, whereas its lower compartment was filled with media
containing 10% FCS or serum-free media as control. After 24h at
371C, cells that migrated through the filter were fixed and stained
with crystal violet containing 10% ethanol. After gentle rinsing
with phosphate-buffered saline, non-migrated cells at the upper
side of the filter were scraped off. Subsequently, the crystal violet
dye retained on the filters was extracted with 10% acetic acid for
5min at room temperature and was colorimetrically measured at
560nm. All experiments were carried out in triplicate and repeated
at least twice.
Cell invasion into matrigel
Cells were seeded onto the top of BioCoat Matrigel Invasion
Chambers (BD Biosciences) containing 8mm pore size PET
membranes covered with matrigel matrix. Medium containing
10% FCS was added to the bottom well of the chambers as a
chemoattractant, whereas serum-free medium was used as a
control. After 24h at 371C and 5% CO2, cells that invaded the
matrigel-coated membrane, located at the lower membrane
surface, were fixed and stained by crystal violet containing 10%
ethanol. Cells of three representative areas in each well were
counted at a magnification of  100. Experiments were carried out
in triplicate and repeated at least twice.
Statistical analysis
Statistical calculations were carried out using GraphPad Prism
software (version 4.00; GraphPad Software, Inc., San Diego, CA,
USA) using an unpaired, two-tailed t-test, considered significant
when Po0.05.
RESULTS
Downregulation of CAR induces loss of a-catenin
Gene expression profiles of DLD1 cells after siRNA-mediated
CAR knockdown (DLD1
CAR-negative) were compared with those of
DLD1
control cells (containing the pSuper vector only), using oligo-
array technology. Setting a threshold of a 1.5-fold difference
between the two cell lines, 1187 genes were found upregulated
and 2318 genes downregulated in the DLD1
CAR-negative cell line.
Among these genes, a-catenin displayed the highest fold change,
showing an 18.54-fold lower expression in the DLD1
CAR-negative
cell line. Western blotting confirmed this finding at the protein
level revealing a reduced a-catenin expression in both the
DLD1
CAR-negative and the IEC-6
CAR-negative cell lines. Furthermore,
transcriptional dependence of a-catenin by CAR was shown
using reverse transcribed (RT)–PCR assays showing a reduced
mRNA expression level of a-catenin in DLD1
CAR-negative and
IEC-6
CAR-negative cells (Figure 1A).
CAR and a-catenin co-localise, yet do not bind directly
Co-immunofluorescence staining for CAR and a-catenin revealed
a ‘honeycomb’ pattern of immunopositivity at the plasma mem-
brane showing a co-localisation of both proteins at this site in
parental- (data not shown) and vector-transfected control cell
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CAR-negative and IEC-6
CAR-negative cells
showed a weak intracellular signal only, comparable with that of
controls stained by secondary antibodies only (data not shown).
After the ectopic expression of a-catenin in DLD1
CAR-negative and
IEC-6
CAR-negative cell lines, a strong intracellular immunopositivity
was noted for a-catenin, yet no signal was detected at the plasma
membrane (Figure 1B). To elucidate whether CAR and a-catenin
proteins bind to each other, we performed co-immunoprecipita-
tions. These analyses showed binding neither when carried out
with the anti-CAR antibody nor when carried out with the anti-a-
catenin antibody. To test whether our experimental conditions are
sufficient to reveal inter-protein binding, additional western
blotting was carried out with an anti-ZO-1 antibody, a known
binding partner of a-catenin (Imamura et al, 1999). These
experiments confirmed the binding of ZO-1 to a-catenin in both
cell lines (Figure 1C).
Impact of CAR and a-catenin on cellular morphology
When cultured under conventional conditions, slight changes
in cell shape were noted for both cell lines: DLD1
CAR-negative
cells appeared rounder and smaller compared with controls,
whereas IEC-6
CAR-negative cells showed a spindlier shape with less
intercellular contact. More dramatic differences were observed
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DLD1
pSuper
CAR
Merge
DLD1 IEC-6
Mock CAR
CAR
ZO-1
IgG -Catenin
-Catenin
Mock CAR IgG -Catenin
-Catenin
pSuperCAR pSuperCAR+-Catenin
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DLD1 IEC-6
-Catenin mRNA
1.5
1
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Figure 1 Expression and localisation of CAR and a-catenin. Protein expression levels of CAR, a-catenin, and b-actin were analysed by western blotting
(A, left panel). Transcriptional regulation of a-catenin after CAR downregulation shown by qRT-PCR with expression levels in mock vector-transfected
controls set to 1 (A, right panel). Immunofluorescence co-staining for CAR and a-catenin reveals the presence of both proteins at the plasma membrane
(arrow) in mock vector-transfected controls (left panels), loss of protein presence at the plasma membrane after CAR downregulation (intracellular signal
intensity equals controls that contain secondary antibodies only) (middle panels), and intracellular immunopositivity for a-catenin after ‘re’-expression of
a-catenin (right panels) (magnification  630) (B). Co-immunoprecipitations indicate no binding between CAR and a-catenin, yet confirm an interaction of
a-catenin and ZO-1 (C).
CAR and a-catenin
K Stecker et al
1576
British Journal of Cancer (2009), 1574–1579 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swhen cells were cultured in matrigel, enabling cells to form three-
dimensional structures. Both cell lines formed amorphous clusters
in sharp contrast to the well-organised-appearing formations of
control cell lines. The ectopic ‘re’-expression of a-catenin in
DLD1
CAR-negative and IEC-6
CAR-negative partially reversed the effects
of CAR knockdown, resulting in bigger-, flatter-, and angular-
appearing cells. When grown in matrigel, these cell lines
established organised formations similar to those of DLD1
control
and IEC-6
control (Figure 2).
Impact of CAR on cell proliferation, migration, and
invasion is mediated by a-catenin
To clarify the functional influence of the CAR–a-catenin inter-
action, we performed in vitro assays after CAR knockdown and the
ectopic ‘re’-expression of a-catenin. Assessment of cell prolifera-
tion revealed significantly higher cell numbers in DLD1
CAR-negative
and IEC-6
CAR-negative compared with controls upon 48h of culti-
vation (DLD1
CAR-negative P¼0.0017; IEC-6
CAR-negative P¼0.0129).
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Figure 2 Impact of CAR and a-catenin on cellular morphology. Cells after CAR knockdown appear round and smaller compared with controls (DLD1) or
display less intercellular attachment sites (IEC-6). In matrigel, cells after CAR knockdown form amorphous clusters in contrast to the organised-appearing
formations of matching controls. Ectopic ‘re’-expression of a-catenin partially reverses the effects seen after CAR knockdown when grown as a monolayer,
and particularly results in organised cell formations similar to those of vector controls when cultured in matrigel. Images show representative results for
DLD1 (A) and IEC-6 (B).
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CAR-negative and
IEC-6
CAR-negative resulted in significantly lower cell numbers
(DLD1
CAR-negative/a-catenin P¼0.0022; IEC-6
CAR-negative/a-catenin
P¼0.0319) (Figure 3A). Using migration assays, DLD1
CAR-negative
and IEC-6
CAR-negative showed significantly increased migratory pro-
perties compared with vector-control cell lines (DLD1
CAR-negative
P¼0.0005; IEC-6
CAR-negative Po0.0001). In contrast, ectopic
‘re’-expression of a-catenin significantly decreased the number of
migrating cells for DLD1
CAR-negative/a-catenin and IEC-6
CAR-negative/a-catenin
(both: Po0.0001) (Figure 3B). To test whether cells migrate in
an FCS-directed manner, we included FCS-free medium controls
for each of the tested cell lines, without noting cell migration
in any case (data not shown). The number of cells invading
into matrigel compared with vector controls increased significantly
for both DLD1
CAR-negative (Po0.0001) and IEC-6
CAR-negative
(Po0.0001) cell lines. Ectopic ‘re’-expression of a-catenin
impaired cell invasion significantly (DLD1
CAR-negative/a-catenin
P¼0.0318; IEC-6
CAR-negative/a-catenin P¼0.0129), yet was not
sufficient to reduce the number of invading cells to the level of
DLD1
control and IEC-6
control cell lines (Figure 3C).
DISCUSSION
This study marks the first report of an impaired a-catenin
expression after downregulation of CAR. On the basis of our data,
it may be speculated that this phenomena crucially affects the
inhibitory effect of CAR on cell proliferation, migration, and
invasion. Moreover, our observations reveal that loss of CAR is
potentially accompanied by substantial changes in cellular
morphology that may also be explained by an impaired presence
of a-catenin.
Our findings reveal that a reduced a-catenin mRNA expression
represents the most prominent feature after downregulation of
CAR. This observation was further validated by our finding of
reduced a-catenin protein presence in DLD1 and IEC-6 cell lines
upon downregulation of CAR. As DLD1 represents a human cancer
cell line and IEC-6 a rat non-transformed small intestinal cell
line, it may be speculated that our results account for a more
general phenomenon. However, differential protein expression of
a-catenin after CAR downregulation differs between cell lines:
after a transient transfection of a CAR-specific siRNA, reduced
a-catenin protein expression was noted in AGS (gastric cancer)
and SW480 (colon cancer), whereas in T84 and HCT116 cells, only
a moderate decline was observed and no changes were noted
in Caco2 (all colon cancer; data not shown). The underlying
mechanisms of these differences remain to be elucidated.
Transcriptional regulation of a-catenin expression after CAR
downregulation potentially marks the main regulatory measure,
as shown by quantitative RT-PCR. However, whether the a-catenin
promoter becomes inactivated upon loss of CAR or changes in
RNA stability occur, remains to be elucidated.
The previously proposed inhibitory effects of CAR on cancer
cell growth and motility have been suggested to result from
an impaired intercellular adhesion (Okegawa et al, 2000; Bruning
and Runnebaum, 2004; Wang et al, 2005). Our data show that
loss of CAR impairs the expression of a-catenin, a protein that
has been extensively studied for its inhibition of cancer cell growth
and motility (Scott and Yap, 2006). Moreover, loss of a-catenin
is frequently described in carcinomas, for example, colon cancer,
significantly correlating with depth of invasion, presence of
metastasis, and an adverse clinical outcome (Ropponen et al,
1999). In line with these reports, we noted an increased
proliferation, migration, and invasion after loss of CAR and
a-catenin. Furthermore, our data show that ‘re’-expression of
a-catenin is sufficient to markedly reverse these effects. Therefore,
it may be speculated that the functional effects on cell growth
and motility after loss of CAR are crucially mediated by a
reduced expression of a-catenin. However, cell invasion has
been reduced to a small extent only on re-expression of a-catenin.
Given that our experimental setting sufficiently reflects cell
invasion, we found that a CAR–a-catenin interaction seems to
be less important in this context compared with cell proliferation
and migration.
Both a-catenin and, recently, CAR have been shown to interact
with the cytoskeleton (Scott and Yap, 2006; Fok et al, 2007). In
agreement with these studies, we noted substantial changes in cell
morphology, particularly when using three-dimensional culturing,
of cell lines after CAR knockdown. The impact of a-catenin on this
phenomenon was shown by the ‘re-’expression of a-catenin, which
resulted in the formation of organised cell formations as opposed
to amorphous clusters after CAR knockdown.
Co-immunofluorescence staining for CAR and a-catenin showed
a co-localisation of both proteins at the plasma membrane in
parental- and vector-transfected control cell lines. However, the
‘re’-expression of a-catenin in CAR-negative cell lines resulted in
DLD1
DLD1
IEC-6
IEC-6
DLD1 IEC-6
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Figure 3 Functional impact of CAR downregulation and a-catenin ‘re’-
expression in DLD1 and IEC-6 cell lines. Proliferation (A), migration (B),
and invasion (C) in DLD1 and IEC-6 were determined after CAR
knockdown and ‘re’-expression of a-catenin in comparison with controls.
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to the plasma membrane. Therefore, we hypothesised that
CAR may recruit a-catenin to the plasma membrane. Yet, co-
immunoprecipitation using either an anti-CAR or an anti-
a-catenin antibody failed to proof a binding of these proteins.
Therefore, reduced presence of other proteins that link a-catenin
to the plasma membrane may account for the intracellular
accumulation of a-catenin seen here. Nevertheless, binding of
CAR to a-catenin may not be excluded entirely, as it might be weak
and/or transient and not be detectable biochemically. Herein, our
findings are potentially in line with a recent study showing that
a-catenin, rather than forming a stable link to actin, acts as
a regulator of actin dynamics and that its binding to the
E-cadherin–b-catenin complex is transient and mutually exclusive
of its interaction with F-actin (Drees et al, 2005).
In conclusion, it may be speculated that the suggested tumour
suppressive function of CAR is at least in part mediated
by regulating the a-catenin expression. Underlying regulatory
mechanisms remain to be elucidated.
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